Aditxt (ADTX) Income from Non-Controlling Interests (2023 - 2026)
Aditxt (ADTX) recorded quarterly Income from Non-Controlling Interests of -$241475.0 in Q1 2026, up 54.4% quarter-over-quarter from -$529572.0 in Q4 2025, and little changed on a YoY basis from -$240797.8 in Q1 2025.
Aditxt (ADTX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
Aditxt's Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at -$241475.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests changed 0.28% year-over-year to -$241475.0; the TTM figure through Mar 2026 stood at -$1.1 million (down 58.43% YoY), while the FY2025 annual figure was -$1.1 million, down 87.05% from the prior year.
- Income from Non-Controlling Interests was -$241475.0 for Q1 2026 at Aditxt, up from -$529572.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$9608.0 in Q4 2023 to a low of -$529572.0 in Q4 2025.
- Historically, Income from Non-Controlling Interests has averaged -$189749.7 across 4 years, with a median of -$150615.5 in 2024.
- The sharpest annual moves came in 2024 and 2026: Income from Non-Controlling Interests slumped 3236.22% in 2024, then climbed 0.28% in 2026.
- A 4-year view of Income from Non-Controlling Interests shows it stood at -$9608.0 in 2023, then plunged by 3236.22% to -$320544.0 in 2024, then sank by 65.21% to -$529572.0 in 2025, then surged by 54.4% to -$241475.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$241475.0 (Q1 2026), -$529572.0 (Q4 2025), and -$162264.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aditxt | 2,485.68 | -2.16 Mn | 2,868.00 | -241,475.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -241,475.00 |
| Dec 31, 2025 | -529,572.00 |
| Sep 30, 2025 | -162,264.00 |
| Jun 30, 2025 | -138,850.00 |
| Mar 31, 2025 | -242,156.00 |
| Dec 31, 2024 | -320,544.00 |
| Sep 30, 2024 | -39,801.00 |
| Jun 30, 2024 | -74,260.00 |
| Mar 31, 2024 | -138,967.00 |
| Dec 31, 2023 | -9,608.00 |